TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Señales de momentum (gestores comparables):
amplitud de titulares +10.5% ·
flujo de acciones +27.5% ·
nuevas posiciones netas +9.5%
· fórmula
Acumulación amplia: acciones en aumento entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 149 | +7 | 367.15M | $12.41B | +9 | −3 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 11.81M | -2.6% | $212.87M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (pasivo) | 8.79M | +3.4% | $157.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Glenview Capital ✦ | 8.46M | -7.7% | $152.38M | 3.2% | ▼ Trim | 2 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 8.11M | -7.0% | $146.20M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 7.57M | Nuevo | $136.37M | 0.5% | New | 1 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 14.90M | +156.7% | $72.24M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 3.65M | -37.9% | $65.85M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 3.62M | +72.2% | $65.27M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 3.47M | +96.1% | $62.50M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 10 | Marshall Wace ✦ | 2.74M | -34.2% | $49.46M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 11 | Norges Bank ✦ (pasivo) | 1.52M | +41.2% | $27.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Duquesne Family Office ✦ | 1.43M | Nuevo | $25.73M | 0.9% | New | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 825.43K | +224.8% | $14.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 715.15K | +419.7% | $12.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 517.71K | -60.8% | $9.33M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Greenlight Capital (DME Capital) ✦ | 324.85K | 0.0% | $5.85M | 0.2% | Held | 2 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 182.10K | -2.2% | $3.28M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 18 | GAMCO Investors ✦ | 129.70K | -3.4% | $2.34M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | ARK Investment Management ✦ | 123.86K | -26.9% | $2.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Bridgewater Associates ✦ | 23.22K | +5.2% | $418,460 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 17.58K | +8.9% | $316,738 | 0.0% | ▲ Add | 2 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Viking Global Investors | $136.37M | 0.5% |
| Duquesne Family Office | $25.73M | 0.9% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 646 tenedores, 666.61M acciones, $16.70B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 2.52K acc. · $98,841
Director · 367.60K acc. · $14.36M
Officer · 4.50K acc. · $174,221
Officer · 314 acc. · $12,153
Officer · 2.50K acc. · $94,077
Director · 415 acc. · $15,459
Officer · 6.95K acc. · $261,224
Officer · 18.60K acc. · $680,291
Director · 17 acc. · $593
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología